INSIDERFilingvia Quantisnow
DataMeds AI Inc. logo

DataMeds AI (MEDS) director Peterson sold 900 shares for $4,212 at $4.68 under a 10b5-1 plan

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Michael L Peterson (director at DataMeds AI Inc., MEDS) reported that they sold 900 shares for $4,212 at $4.68, and received 10,721 shares on Apr 19, 2021. After these transactions the filing shows 17,008 shares held directly.

Reporting person
Peterson Michael L
Common stock and other non-derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Apr 19, 2021Open-market sale (S)Common stock1, 2-900$4.68$4,2126,287 direct
Apr 19, 2021Grant or award (A)Common stock3, 4+10,721$5.13$55K17,008 direct

Holdings before and after

  • Common stock: 7,187 to 17,008 direct

Footnotes from the filing

  1. 1. The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the April 2021 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3.
  2. 2. This transaction was executed in multiple trades at prices ranging from $4.63 to $4.77, with the price reported above reflecting the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was affected.
  3. 3. Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on July 1 and October 1, 2021 and January 1 and April 1, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d).
  4. 4. Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors.

Transaction codes in this filing

Open-market sale:
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Grant or award:
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ

What did Peterson report in this MEDS Form 4?

Michael L Peterson (director at DataMeds AI Inc., MEDS) reported that they sold 900 shares for $4,212 at $4.68, and received 10,721 shares on Apr 19, 2021. After these transactions the filing shows 17,008 shares held directly.

How many MEDS shares does Peterson hold after this filing?

The filing shows 17,008 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.

Was this MEDS insider sale made under a 10b5-1 plan?

The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.

What does transaction code S mean on an SEC Form 4?

Code S marks a sale in the open market or a private deal. The insider received cash for these securities.

Historical context for MEDS

Earlier insider filings at MEDS

Quantisnow market dataNASDAQ
DataMeds AI Inc. logo
MEDS
DataMeds AI Inc.
Market cap
30-day
Sector
Health Care
Industry
Other Pharmaceuticals
Get push alerts for MEDS

Follow MEDS and get a push notification the moment its next story breaks.

Full MEDS profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MEDS (DataMeds AI Inc.) and more on Quantisnow.